Author: Zacks Small Cap Research

1676869707189690 / 885 POSTS
By John Vandermosten, CFANASDAQ:ATRSREAD THE FULL ATRS RESEARCH REPORTFDA Approval of Teva Generic Epinephrine PenOn August 16, 2018 the FDA granted approval of Teva’s (NYSE:TEVA) epinephrine auto-injector for severe allergies. Both the 0.3 mg and th ...
By David Bautz, PhDNASDAQ:MTFBREAD THE FULL MTFB RESEARCH REPORTBusiness UpdateMotif Bio Plc (NASDAQ:MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s le ...
OTC:LDSRRaleigh, North Carolina-based Data443 Risk Mitigation, a wholly owned subsidiary of LandStar, Inc. (OTC:LDSR), is a technology company that is developing an ambitious portfolio of cyber-security products and service offerings for blockchain, ...
By David Bautz, PhDNYSE:APHBREAD THE FULL APHB RESEARCH REPORTBusiness UpdateMeeting with the FDA to Determine Regulatory Path for AB-SA01 and AB-PA01On August 9, 2018, AmpliPhi Biosciences Corp. (NYSE:APHB) provided a business update concerning the ...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateContraFect Corp. (NASDAQ:CFRX) is currently conducting a Phase 2 clinical trial of CF-301, the company’s lead lysin product candidate, in patients with bacteremia, includi ...
NASDAQ:CKPTCheckpoint Therapeutics (NASDAQ:CKPT) announced today that it will present results from the CK-101 Phase I/II program at the World Conference on Lung Cancer on Monday, September 24 in Toronto, Canada. CK-101 is the company’s lead candidate ...
By Steven Ralston, CFANASDAQ:DSKEREAD THE FULL DSKE RESEARCH REPORTSUMMARY OF RECENT EVENTS‣ On August 9th, Daseke (NASDAQ:DSKE) announced financial results for the second quarter ending June 30, 2018.     • Total revenues increased 91.0%, primarily ...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdateVK5211 UpdateIn 2017, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced positive topline results from the Phase 2 study of VK5211, a selective androgen receptor modulator ...
By David Bautz, PhDNASDAQ:OPNTREAD THE FULL OPNT RESEARCH REPORTBusiness UpdateOPNT003 UpdateEarlier in 2018, Opiant (NASDAQ:OPNT) announced the receipt of a $7.4 million grant from the National Institute on Drug Abuse (NIDA) to fund the development ...
By Brian Marckx, CFAOTC:SMLRREAD THE FULL SMLR RESEARCH REPORTQ2 2018 Results: Huge Beat to Our #s. Huge Upward Revisions to Our Model and Price Target…Semler’s (OTC:SMLR) results in each of the last few quarters have indicated that the company could ...
1676869707189690 / 885 POSTS